摘要
奥鲁替尼是由Forma Therapeutics研发的靶向突变异柠檬酸脱氢酶1(IDH1)的强效、选择性、口服小分子抑制剂,2022年12月1日FDA批准上市,用于治疗具有易感性IDH1突变的复发和难治性急性髓系白血病成年患者.临床研究显示,奥鲁替尼疗效较好,耐受性良好,常见不良反应为恶心、疲劳不适、关节痛、便秘、白细胞增多症、呼吸困难、发热、皮疹、黏膜炎、腹泻和转氨酶升高.本文就奥鲁替尼的作用机制、药动学、临床疗效评价和不良反应等进行综述,旨在为临床合理用药提供参考.
Abstract
Olutasidenib is a potent,selective,oral small molecule inhibitor targeting mutant isocitrate dehydrogenase-1(IDH1),which was developed by Forma Therapeutics.It is approve by the FDA on December 1,2022,for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.Clinical studies have shown that olutasidenib has a good efficacy and safety profile.Common adverse effects include nausea,fatigue discomfort,ar-thralgia,constipation,leukocytosis,dyspnea,fever,rash,mucositis,diarrhea,and elevated transaminase.In this paper,the mechanism of action,pharmacokinetics,clinical efficacy evaluation,and adverse reactions of olutinib were reviewed in order to provide reference for clinical rational drug use.
NETL
NSTL
万方数据